Sign In
OZYMF.US
id: 735, Created by Stan Vick, Scout

Orphazyme A/S (ORPH) $2.5M IPO Settlement

How it works?
  1. Company agreed to settle with investors to avoid further litigation
  2. We prepare documents and claim payout for you
N.D. Illinois
Court
1:21-CV-03640
Case number
29 Sept 2020
Class period Start
04 Nov 2021
Class period End
17 Jan 2024
Claim deadline
Orphazyme A/S (ORPH) agreed to settle $2.5 million with investors to end claims over misleading statements during its IPO in 2020.
Alleged Offence
Misleading Statements, 
Failure to Disclose, 
Omissions
Suspected Party
Directors, 
Management
Security Type
Depository Securities (ADS, ADR, GDR)
Trade Direction
Long
Payout per Share
0.12
Filing date
09 July 2021
Plaintiffs
Marko Busic
Attorneys
Bronstein, Gewirtz & Grossman, LLC (New York, NY), Pomerantz LLP (Chicago, IL)
Defendants
Christophe Bourdon, Anders Vadsholt, Kim Stratton, Thomas Blaettler, Molly Painter, Georges Gemayel, Bo Jesper Hansen, Martin Bonde, Rémi Droller, Sten Verland, Martijn Kleijwegt, Anders Hedegaard, Catherine Moukheibir, Carrolee Barlow
Judge
Hon. John F. Kness
Administrator
A.B. Data Ltd
Settlement agreement date
2023-05-12
Trades matching type
FIFO
+$2,500,000
Total Settlement Amount
Created by Stan Vick, Scout

Orphazyme A/S

Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorpo...

    Ticker
    OZYMF.US
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    Ole MaalOees Vej 3, Copenhagen, Denmark, 2200